Mark Bounthavong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5910042/publications.pdf

Version: 2024-02-01

361388 361001 1,445 61 20 35 citations g-index h-index papers 63 63 63 1993 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implementation Science, 2019, 14, 11.	6.9	370
2	Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S168-S179.e4.	1. 5	70
3	Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. American Journal of Health-System Pharmacy, 2014, 71, 960-965.	1.0	54
4	Efficacy and safety of linezolid in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Current Medical Research and Opinion, 2010, 26, 407-421.	1.9	52
5	Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S68-S72.	1.5	48
6	Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry, 2021, 78, 767.	11.0	45
7	Revisiting the medication possession ratio threshold for adherence in lipid management. Current Medical Research and Opinion, 2013, 29, 175-180.	1.9	43
8	Cost-Effectiveness Analysis of Linezolid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus: Complicated Skin and Skin Structure Infection Using Bayesian Methods for Evidence Synthesis. Value in Health, 2011, 14, 631-639.	0.3	41
9	Implementing a comprehensive, 24-hour emergency department pharmacy program. American Journal of Health-System Pharmacy, 2009, 66, 1943-1947.	1.0	40
10	Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and & p; beta; lactamase-inhibitor combination. Infection and Drug Resistance, 2013, 6, 215.	2.7	40
11	Development and validation of PSPSQ 2.0 measuring patient satisfaction with pharmacist services. Research in Social and Administrative Pharmacy, 2015 , 11 , $487-498$.	3.0	40
12	Costâ€utility analysis of bevacizumab versus ranibizumab in neovascular ageâ€related macular degeneration using a Markov model. Journal of Evaluation in Clinical Practice, 2012, 18, 247-255.	1.8	36
13	Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant <i>Staphylococcus aureus</i> complicated skin and soft tissue infections using a decision analytic model. International Journal of Clinical Practice, 2009, 63, 376-386.	1.7	30
14	Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 279-285.	4.9	28
15	An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Research in Social and Administrative Pharmacy, 2017, 13, 530-538.	3.0	28
16	Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Services Research, 2019, 54, 1055-1064.	2.0	28
17	Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up―Clinic. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 318-326.	0.9	27
18	Clinical dashboard development and use for academic detailing in the U.S. Department of Veterans Affairs. Journal of the American Pharmacists Association: JAPhA, 2019, 59, S96-S103.e3.	1.5	27

#	Article	IF	Citations
19	Cost Utility of Tumour Necrosis Factor- \hat{l}_{\pm} Inhibitors for Rheumatoid Arthritis. Pharmacoeconomics, 2012, 30, 575-593.	3.3	26
20	Approach to Addressing Missing Data for Electronic Medical Records and Pharmacy Claims Data Research. Pharmacotherapy, 2015, 35, 380-387.	2.6	23
21	Association of Copayment with Likelihood and Level of Adherence in New Users of Statins: A Retrospective Cohort Study. Journal of Managed Care Pharmacy, 2014, 20, 43-50.	2.2	20
22	Comparison of an Intensive Pharmacist-Managed Telephone Clinic With Standard of Care for Tobacco Cessation in a Veteran Population. Health Promotion Practice, 2014, 15, 512-520.	1.6	18
23	Academic Detailing to Improve Opioid Safety: Implementation Lessons from a Qualitative Evaluation. Pain Medicine, 2018, 19, S46-S53.	1.9	17
24	Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. Journal of Evaluation in Clinical Practice, 2007, 13, 453-460.	1.8	16
25	Retrospective Evaluation of Inpatient Celecoxib Use After Total Hip and Knee Arthroplasty at a Veterans Affairs Medical Center. Journal of Arthroplasty, 2012, 27, 1033-1040.	3.1	16
26	Relative costs of anesthesiologist prepared, hospital pharmacy prepared and outsourced anesthesia drugs. Journal of Clinical Anesthesia, 2017, 36, 178-183.	1.6	16
27	Virtual academic detailing (e-Detailing): A vital tool during the COVID-19 pandemic. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e95-e99.	1.5	15
28	Measuring patient satisfaction in the pharmacy specialty immunization clinic: a pharmacist-run Immunization Clinic at the Veterans Affairs San Diego Healthcare System. International Journal of Pharmacy Practice, 2010, 18, 100-7.	0.6	15
29	Association of Polypharmacy and Statin New-User Adherence in a Veterans Health Administration Population. Annals of Pharmacotherapy, 2013, 47, 1253-1259.	1.9	14
30	Association of Copayment and Statin Adherence Stratified by Socioeconomic Status. Annals of Pharmacotherapy, 2013, 47, 1463-1470.	1.9	14
31	Evaluating the Impact of a Clinical Decision Support Tool to Reduce Chronic Opioid Dose and Decrease Risk Classification in a Veteran Population. Annals of Pharmacotherapy, 2018, 52, 325-331.	1.9	14
32	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics, 2018, 36, 1463-1473.	3.3	14
33	Identifying healthâ€related quality of life (HRQL) domains for multiple chronic conditions (diabetes,) Tj ETQq1 i	1 0.784314 1.8	rgBT /Over o
34	Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes. Diabetes and Metabolism, 2014, 40, 284-291.	2.9	13
35	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	3.0	13
36	Association Between Statin Adherence and Cholesterol Level Reduction from Baseline in a Veteran Population. Pharmacotherapy, 2013, 33, 1044-1052.	2.6	12

#	Article	IF	Citations
37	Economic evaluation of home-based telebehavioural health care compared to in-person treatment delivery for depression. Journal of Telemedicine and Telecare, 2018, 24, 84-92.	2.7	12
38	Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. Journal of General Internal Medicine, 2022, 37, 3594-3602.	2.6	12
39	Cost–effectiveness of linezolid in methicillin-resistantStaphylococcus aureusskin and skin structure infections. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 683-698.	1.4	9
40	Impact of academic detailing on benzodiazepine use among veterans with posttraumatic stress disorder. Substance Abuse, 2020, 41, 101-109.	2.3	8
41	Evaluation of Multidisciplinary Tobacco Cessation Training Program in a Large Health Care System. American Journal of Health Education, 2015, 46, 165-173.	0.6	7
42	Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injury. ClinicoEconomics and Outcomes Research, 2010, 2, 15.	1.9	6
43	Comparison of naloxone prescribing patterns due to educational outreach conducted by full-time and part-time academic detailers at the U.S. Veterans Health Administration. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 639-646.	1.5	6
44	Academic Detailing to Reduce Sedative-Hypnotic Prescribing in Older Veterans. Journal of Pharmacy Practice, 2021, 34, 287-294.	1.0	6
45	Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 297-303.	1.5	6
46	Comparison of virtual to in-person academic detailing on naloxone prescribing rates at three U.S. Veterans Health Administration regional networks. International Journal of Medical Informatics, 2022, 161, 104712.	3.3	6
47	Impact of Implementing an Academic Detailing Program on Opioid-Benzodiazepine Co-Prescribing Trends at the U.S. Department of Veterans Affairs. Pain Medicine, 2021, 22, 1426-1434.	1.9	5
48	Improved Patient-Reported Medication Adherence, Patient Satisfaction, and Glycemic Control in a Collaborative Care Pharmacist-Led Diabetes "Tune-Up―Clinic. International Journal of Environmental Research and Public Health, 2021, 18, 9242.	2.6	5
49	Implementation of a pharmacy-led virtual academic detailing program at the US Veterans Health Administration. American Journal of Health-System Pharmacy, 2022, 79, 909-917.	1.0	4
50	A tobacco cessation treatment model using telehealth: a pilot evaluation in Veterans. Journal of Telemedicine and Telecare, 2014, 20, 161-163.	2.7	3
51	High- vs low-dose oxytocin in lean and obese women: a double-blinded randomized controlled trial. American Journal of Obstetrics & Synecology MFM, 2022, 4, 100627.	2.6	3
52	Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 80.	2.2	2
53	The Authors' Reply. Pharmacoeconomics, 2012, 30, 977-978.	3.3	1
54	Emergency Medical Services Naloxone Administration: Many Unknowns and Opportunities. Annals of Internal Medicine, 2017, 167, 890.	3.9	1

#	Article	IF	CITATIONS
55	Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey. Journal of General Internal Medicine, 2020, 35, 1334-1336.	2.6	1
56	Transferring Key Success Factors from Ambulatory Care into the Community Pharmacy in the United States. Pharmacy (Basel, Switzerland), 2021, 9, 116.	1.6	1
57	Exploring Providers' Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs. Journal of Pharmacy Practice, 2021, , 089719002110532.	1.0	1
58	Risk of Negative Health Outcomes and High Costs for People With Diabetes and Unmet Psychological Needs in the United States. Diabetes Spectrum, 2022, 35, 207-215.	1.0	1
59	Longitudinal Effects on Metabolic Biomarkers in Veterans 12 Months Following Discharge from Pharmacist-Provided Diabetes Care: A Retrospective Cohort Study. Pharmacy (Basel, Switzerland), 2022, 10, 63.	1.6	1
60	Commentary on Rege <i>et al</i> . (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities. Addiction, 2018, 113, 2316-2317.	3.3	0
61	New start versus continuing users on aripiprazole: implications for policy. American Journal of Managed Care, 2015, 21, e43-50.	1.1	0